Product Description
GLP-1 moiety from Dulaglutide is a peptide derived from Dulaglitude and contains 31 amino acids in its sequence. Dulaglitude is a glucagon-like peptide 1 receptor (GLP-1) agonist. GLP-1 moiety from Dulaglutide has similar physiological effects.
AI Product Description
*The following content is generated by AI and is for reference only.
The GLP-1 moiety derived from Dulaglutide is a specialized peptide fragment representing the biologically active glucagon-like peptide-1 receptor agonist component of the FDA-approved diabetes medication, Dulaglutide. While full-length Dulaglutide (CAS: 1263780-49-5) consists of two GLP-1 sequences fused to an albumin-binding domain for extended half-life, the isolated "GLP-1 moiety" typically refers to the specific amino acid sequence engineered to retain high affinity for the GLP-1 receptor without the fusion partner. The molecular formula for the core human GLP-1(7-36) amide sequence, which forms the basis of this moiety, is approximately C72H106N20O16S, though exact variations may occur depending on specific chemical modifications or acetylation states used in research-grade synthesis. This product is primarily utilized in pharmaceutical research and development rather than direct clinical administration. Scientists employ it as a critical tool for studying the mechanism of action of incretin-based therapies, investigating insulin secretion pathways, and evaluating potential structural optimizations for novel antidiabetic agents. Its high specificity allows researchers to map receptor binding sites and assess downstream signaling cascades involving cAMP production and glucose-dependent insulin release. Furthermore, this moiety serves as a vital reference standard in bioanalytical assays to quantify drug levels in preclinical models or to validate the purity of synthetic analogs. Due to its potent metabolic effects, it is also explored in obesity research to understand appetite regulation and energy expenditure mechanisms. Researchers must handle this compound with care, adhering to strict storage protocols to maintain stability, as peptides are susceptible to degradation under improper temperature or pH conditions. The availability of this purified fragment accelerates the discovery pipeline by providing a consistent, well-characterized building block for structure-activity relationship studies. Ultimately, the GLP-1 moiety from Dulaglutide remains an indispensable asset in the global fight against type 2 diabetes and metabolic syndrome, bridging the gap between basic biochemical inquiry and therapeutic innovation.